0.034
0.00 (13.33%)
| Previous Close | 0.030 |
| Open | 0.040 |
| Volume | 1,622,406 |
| Avg. Volume (3M) | 16,325,921 |
| Market Cap | 1,598,747 |
| Price / Book | 0.430 |
| 52 Weeks Range | |
| Earnings Date | 8 Apr 2026 |
| Diluted EPS (TTM) | -0.940 |
| Current Ratio (MRQ) | 3.72 |
| Operating Cash Flow (TTM) | -16.75 M |
| Levered Free Cash Flow (TTM) | -10.69 M |
| Return on Assets (TTM) | -38.60% |
| Return on Equity (TTM) | -555.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Iterum Therapeutics plc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.0 |
| Average | 0.50 |
|
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.03% |
| % Held by Institutions | 6.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Apollon Financial, Llc | 31 Dec 2025 | 630,250 |
| Alchemi Wealth, Llc | 31 Dec 2025 | 268,886 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |